Q-Med introduces two new Restylane® products with lidocaine

Q-Med is proud to announce Restylane® Lidocaine and Restylane Perlane™ Lidocaine as the latest additions to the Restylane range. Frown lines, wrinkles around the nose, mouth and between the eyes can be quickly managed with the new products Restylane Lidocaine and Restylane Perlane Lidocaine. Through the addition of 0.3 percent lidocaine the products offer maximum effect with a minimum of discomfort during treatment. Lidocaine is a swift and safe local anaesthetic that is widely used by physicians to numb treatment sites. Since we all experience pain differently, it is a comfort to have the choice of a Restylane treatment with integrated pain relief. The results from a randomised, double-blind, split face study shows that 90 percent of the subjects assessed Restylane Perlane Lidocaine as being the more comfortable treatment with regard to pain at injection when compared to injection without the addition of lidocaine. The filler effect was shown in the same study to be equivalent to the corresponding product without lidocaine. “The Restylane family of products is among the world’s most widely used dermal fillers. With Restylane Lidocaine and Restylane Perlane Lidocaine consumers can now get rid of any unwanted wrinkles and experience more comfort during a treatment that is quick, safe and long lasting” says Bengt Ågerup, founder and CEO of Q-Med. The Restylane gel is a crystal-clear gel based on stabilized hyaluronic acid. Hyaluronic acid is found naturally in the skin with the main function to bind water. Bengt Ågerup has patented the unique NASHA™ technology, which stabilizes hyaluronic acid, making it last longer and at the same time be similar to the body’s own hyaluronic acid. Restylane has been on the market for more than 12 years and is the most extensively studied dermal filler in the world. To date, more than 10 million treatments have been performed and a large number of scientific studies, including more than 10 randomized clinical trials, have been published in peer reviewed journals. Restylane has, in a recent study, proven effect lasting up to 18 months with one retreatment. Queries should be addressed to: Bengt Ågerup, President and CEO Tel: +46 70 974 9025 Alexander Kotsinas, Vice President and CFO Tel: +46 735 00 1111